Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05093400 · ClinicalTrials.gov registry record

Oropharynx (OPX) Salivary Biomarker Study

A clinical trial of Healthy, sponsored by Mayo Clinic.

Completed
Registry status
100
Enrollment target
1
Study location

NCT05093400: Completed study of Healthy, sponsored by Mayo Clinic.

NCT05093400 is a study of Healthy that has completed, run by Mayo Clinic. The registered enrollment target is 100 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05093400, a study of Healthy, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to analyze certain biomarkers to look at the relationship between HPV in the saliva, stage at presentation, and a potential self-test compared to saliva of non-cancerous participants.

Conditions Studied

Interventions

  • OTHER no intervention

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-09-17
Est. Completion 2023-05-05

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT05093400

The ClinicalTrials.gov registry entry for NCT05093400 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (85% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which no intervention is the first listed.

NCT05093400 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT05093400 about?

NCT05093400 is a clinical study titled "Oropharynx (OPX) Salivary Biomarker Study". The goal of this study is to analyze certain biomarkers to look at the relationship between HPV in the saliva, stage at presentation, and a potential self-test compared to saliva of non-cancerous participants.

What is the current status of trial NCT05093400?

This trial is currently completed. The enrollment target is 100 participants. The study started on 2021-09-17. Estimated completion is 2023-05-05.

What conditions does trial NCT05093400 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT05093400?

The interventions under investigation include: no intervention (OTHER).

Who is sponsoring clinical trial NCT05093400?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05093400 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.